Healthcare · METROHL
Diagnostics
from 577 today
Metropolis’ Q1FY27 was broadly in-line with our expectation, with revenue growing at 16.6% led by an uptick in patient volumes and improvement in test mix. We raise FY28E EPS by ~1%, factoring in better margins, and retain BUY with a DCF-based TP of INR 675.
Metropolis Healthcare reported broadly in-line 1QFY27 performance, with revenue growing 17% YoY to INR 4.5bn. We maintain our FY27E/28E EPS, roll forward our valuation and value METROHL at 39x 1HFY29E EPS, arriving at a revised TP of INR 630 with a Hold recommendation.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
